Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Reshma Kewalramani

- PMLiVE

Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes

Vertex has released results from its phase 1/2 trial for VX-880, a stem-cell-derived therapy that restores insulin production

- PMLiVE

Vertex expands further into cell and genetic therapies with a deal worth up to $1.2bn

A new deal will see Vertex harness Arbor Biotechnologies gene-editing technology to enhance its discovery efforts

- PMLiVE

Merck spin-off Organon sees share price jump at Q2 results

Strong growth in women’s health and biosimilars is driving the new company, which expects 2021 growth in the “low to mid-single digit range”

- PMLiVE

Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’

Sales grew by 19% in the second quarter as key products begin to recover from the impact of the pandemic

- PMLiVE

GSK beats expectations thanks to strong vaccine sales in Q2

GSK's vaccine business was up by 39% to £1.6bn thanks to the strong growth (46%) of its meningitis vaccine

- PMLiVE

AZ raises full-year guidance after completing Alexion acquisition in Q2

Total revenue was up by 31% to $8.2bn and also increased by 24% to $15.2bn for the half year

- PMLiVE

Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb

COVID-19 vaccine generated $7.8bn in the second quarter of 2021 alone

- PMLiVE

Novartis sees demand returning to pre-COVID-19 levels in Q2 results

Swiss pharma company also provided key updates on a number of drug candidates in its pipeline

- PMLiVE

Vertex to lead development of CRISPR Therapeutics-partnered gene therapy

Amended agreement sees Vertex take control of gene therapy programme

- PMLiVE

Vertex gains FDA fast track designation for diabetes stem cell therapy

Vertex says VX-880 has potential to restore pancreatic islet cell function, including insulin production, in type 1 diabetes patients

- PMLiVE

Moderna inks R&D agreements with Vertex and Chiesi

Biotech agrees to separate deals for the development of gene-editing and mRNA therapies

- PMLiVE

Vertex’s triple combination CF therapy to become available on the NHS

The drug will immediately become available to thousands of cystic fibrosis patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links